Logo image of TGTX

TG THERAPEUTICS INC (TGTX) Stock Overview

USA - NASDAQ:TGTX - US88322Q1085 - Common Stock

36.66 USD
+0.1 (+0.27%)
Last: 10/2/2025, 8:00:01 PM
36.66 USD
0 (0%)
After Hours: 10/2/2025, 8:00:01 PM

TGTX Key Statistics, Chart & Performance

Key Statistics
52 Week High46.48
52 Week Low21.16
Market Cap5.82B
Shares158.67M
Float143.20M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.37
PE99.08
Fwd PE18.88
Earnings (Next)11-03 2025-11-03
IPO12-14 1995-12-14
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


TGTX short term performance overview.The bars show the price performance of TGTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10

TGTX long term performance overview.The bars show the price performance of TGTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400 500

The current stock price of TGTX is 36.66 USD. In the past month the price increased by 14.96%. In the past year, price increased by 64.91%.

TG THERAPEUTICS INC / TGTX Daily stock chart

TGTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 22.34 417.90B
AMGN AMGEN INC 13.64 160.11B
GILD GILEAD SCIENCES INC 14.28 137.18B
VRTX VERTEX PHARMACEUTICALS INC 24.14 104.83B
REGN REGENERON PHARMACEUTICALS 13.15 63.59B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.43B
ARGX ARGENX SE - ADR 85.39 48.45B
ONC BEONE MEDICINES LTD-ADR 6.03 41.03B
INSM INSMED INC N/A 32.30B
BNTX BIONTECH SE-ADR N/A 25.12B
BIIB BIOGEN INC 9.7 22.76B
NTRA NATERA INC N/A 21.99B

About TGTX

Company Profile

TGTX logo image TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 370 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

Company Info

TG THERAPEUTICS INC

3020 Carrington Mill Blvd., Suite 475

Morrisville NORTH CAROLINA 10014 US

CEO: Michael S. Weiss

Employees: 370

TGTX Company Website

TGTX Investor Relations

Phone: 18775758489

TG THERAPEUTICS INC / TGTX FAQ

What is the stock price of TG THERAPEUTICS INC today?

The current stock price of TGTX is 36.66 USD. The price increased by 0.27% in the last trading session.


What is the ticker symbol for TG THERAPEUTICS INC stock?

The exchange symbol of TG THERAPEUTICS INC is TGTX and it is listed on the Nasdaq exchange.


On which exchange is TGTX stock listed?

TGTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TG THERAPEUTICS INC stock?

15 analysts have analysed TGTX and the average price target is 42.84 USD. This implies a price increase of 16.86% is expected in the next year compared to the current price of 36.66. Check the TG THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TG THERAPEUTICS INC worth?

TG THERAPEUTICS INC (TGTX) has a market capitalization of 5.82B USD. This makes TGTX a Mid Cap stock.


How many employees does TG THERAPEUTICS INC have?

TG THERAPEUTICS INC (TGTX) currently has 370 employees.


What are the support and resistance levels for TG THERAPEUTICS INC (TGTX) stock?

TG THERAPEUTICS INC (TGTX) has a support level at 36.58 and a resistance level at 36.67. Check the full technical report for a detailed analysis of TGTX support and resistance levels.


Is TG THERAPEUTICS INC (TGTX) expected to grow?

The Revenue of TG THERAPEUTICS INC (TGTX) is expected to grow by 83.91% in the next year. Check the estimates tab for more information on the TGTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy TG THERAPEUTICS INC (TGTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TG THERAPEUTICS INC (TGTX) stock pay dividends?

TGTX does not pay a dividend.


When does TG THERAPEUTICS INC (TGTX) report earnings?

TG THERAPEUTICS INC (TGTX) will report earnings on 2025-11-03.


What is the Price/Earnings (PE) ratio of TG THERAPEUTICS INC (TGTX)?

The PE ratio for TG THERAPEUTICS INC (TGTX) is 99.08. This is based on the reported non-GAAP earnings per share of 0.37 and the current share price of 36.66 USD. Check the full fundamental report for a full analysis of the valuation metrics for TGTX.


What is the Short Interest ratio of TG THERAPEUTICS INC (TGTX) stock?

The outstanding short interest for TG THERAPEUTICS INC (TGTX) is 17.17% of its float. Check the ownership tab for more information on the TGTX short interest.


TGTX Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to TGTX. When comparing the yearly performance of all stocks, TGTX is one of the better performing stocks in the market, outperforming 86.82% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TGTX Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to TGTX. TGTX has only an average score on both its financial health and profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TGTX Financial Highlights

Over the last trailing twelve months TGTX reported a non-GAAP Earnings per Share(EPS) of 0.37. The EPS decreased by -38.33% compared to the year before.


Industry RankSector Rank
PM (TTM) 13.31%
ROA 8.6%
ROE 21.87%
Debt/Equity 0.89
Chartmill High Growth Momentum
EPS Q2Q%325%
Sales Q2Q%92.13%
EPS 1Y (TTM)-38.33%
Revenue 1Y (TTM)30.96%

TGTX Forecast & Estimates

15 analysts have analysed TGTX and the average price target is 42.84 USD. This implies a price increase of 16.86% is expected in the next year compared to the current price of 36.66.

For the next year, analysts expect an EPS growth of 465.86% and a revenue growth 83.91% for TGTX


Analysts
Analysts78.67
Price Target42.84 (16.86%)
EPS Next Y465.86%
Revenue Next Year83.91%

TGTX Ownership

Ownership
Inst Owners64.52%
Ins Owners9.73%
Short Float %17.17%
Short Ratio10.32